Form 6-K GENETIC TECHNOLOGIES For: Nov 19

�

FORM�6-K

�

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

�

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

�

dated November�19, 2014

�

Commission File Number 0-51504

�

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

�

N/A

(Translation of Registrant�s Name)

�

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

�

Indicate by check mark whether the registrant files or will file annual reports under cover of Form�20-F or Form�40-F.

�

Form�20-F x

Form�40-F o

�

Indicate by check mark if the registrant is submitting the Form�6-K in paper as permitted by Regulation S-T Rule�101(b)(1):�o

�

Indicate by check mark if the registrant is submitting the Form�6-K in paper as permitted by Regulation S-T Rule�101(b)(7): o

�

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule�12g3-2(b)�under the Securities Exchange Act of 1934.

�

Yes o

No x

�

If �Yes� is marked, indicate below the file number assigned to the registrant in connection with Rule�12g3-2(b):� Not applicable.

�

�

�

SIGNATURES

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

�

�

Date:� November�19, 2014

�

�

�	GENETIC TECHNOLOGIES LIMITED
�	�	�
�	�	�
�	By:	/s/ Bronwyn Christie
�	�	Name:	Bronwyn Christie
�	�	Title:	Company Secretary

�

2

�

EXHIBIT�INDEX

�

Exhibit	�	Description�of�Exhibit
�	�	�
99.1	�	ASX Announcement, November�19, 2014

�

3

�

Exhibit 99.1

�

�

ASX ANNOUNCEMENT

19 November�2014

�

Divestment of Australian heritage business completed

�

Melbourne, Australia; 19 November�2014: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, �Company� ) is pleased to announce that it has completed the sale of its heritage Australian Genetics business (�Australian Genetics�) to Specialist Diagnostics Services Ltd (�SDS�), the wholly owned pathology subsidiary of Primary Health Care Ltd. Under the terms of sale, SDS acquired the Australian Genetics business for $2.0M, in cash.

�

The divestment of the Australian Genetics business follows the Company�s announcement on 15 September�2014, of plans to sell non-core assets and focus business activities on the US molecular diagnostics market and commercialisation of the Company�s lead breast cancer risk test BREVAGenplus�.

�

Genetic Technologies� Chief Executive Officer Alison Mew commented on the sale saying, �The divesture of the Australian Genetics business represents another material milestone in our transformation to becoming a streamlined and focused molecular diagnostics company committed to the commercialisation of our flagship breast cancer risk test, BREVAGenplus. Implementation of the restructure plans continue and are on track for completion over the next quarter.�

�

FOR FURTHER INFORMATION PLEASE CONTACT

�

Ms Alison Mew	Candice Knoll (USA)
Chief Executive Officer	Blueprint Life Science Group
�	�
Genetic Technologies Limited	+1 (415) 375 3340, Ext. 105
Phone: +61 3 8412 7000	�

�

About Genetic Technologies Limited

�

Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting.� The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE).� Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. �Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women�s health.� Phenogen�s lead product, BREVAGen�, is a first in class, clinically validated risk assessment test for non-familial breast cancer.

�

For more information, please visit http://www.gtglabs.com and http://www.phenogensciences.com

�

Safe Harbor Statement

�

Any statements in this press release that relate to the Company�s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act� The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees.� Since this information may involve risks and uncertainties and are subject to

�

Genetic Technologies Limited � Website: www.gtglabs.com � Email: [email protected] �ABN 17 009 212 328

Registered Office � 60-66 Hanover Street Fitzroy Victoria 3065 Australia � Postal Address P.O.�Box 115 Fitzroy Victoria 3065 Australia

Phone +61 3 8412 7000 � Fax +61 3 8412 7040

�

�

change at any time, the Company�s actual results may differ materially from expected results.� Additional risks associated with Genetic Technologies� business can be found in its periodic filings with the SEC.

�

Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit www.gtglabs.com.

�

Safe Harbor Statement

�

Any statements in this press release that relate to the Company�s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. �The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees.� Since this information may involve risks and uncertainties and are subject to change at any time, the Company�s actual results may differ materially from expected results.� Additional risks associated with Genetic Technologies� business can be found in its periodic filings with the SEC.

�